Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on June 2, 2011. The report announces financial results for the fiscal quarter and fiscal year ended March 31, 2011. The company is incorporated in Delaware and operates from Petaluma, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) containing the full financial results, but the data itself is not included in this document.
Material Changes
No specific material changes or comparative financial data versus prior periods are detailed in this filing text. The document serves solely as a notification of the results announcement.
Guidance, Outlook, and Risks
The filing includes forward-looking statements regarding commercial progress, technology development, and future financial performance. Management highlights significant risks that could cause actual results to vary, including:
- Changes in regulatory clinical and guideline developments.
- Insufficient scientific data to meet regulatory standards or failure to receive required approvals.
- Inability to replicate clinical results in actual patient settings.
- Challenges to patent protection by competitors.
- Market size and penetration uncertainties.
- Insufficient revenues to fund further development or meet future capital needs.
- Complexities in varying product formulations and diverse international regulatory requirements.
The company disclaims any obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) in the referenced press release (Exhibit 99.1) dated June 1, 2011.
- Confirm the status of regulatory approvals for the company's products.
- Assess the company's current cash runway and ability to secure additional funding.
- Review the annual report on Form 10-K for the year ended March 31, 2010, for detailed risk factors.